Biomarkers for lung cancer
AssigneeNovartis AG
InventorsEdoardo Missiaglia, Simona Rossi, Pratyaksha Wirapati, Werner Kroll
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to methods for determining a prognosis of early stage lung cancer in an individual using one or more biomarkers.
Claims35
A method for prognosing a subject with non-small cell lung cancer (NSCLC) comprising:
- obtaining a test sample from a subject suffering from NSCLC following surgical resection;
- determining the expression level of at least three or more biomarkers identified in each of Table 1, Table 2 or Table 3;
- and
- analyzing the expression level to generate a risk score, wherein the risk score can be used to provide a prognosis of the subject.
A method for prognosing a subject with non-small cell lung cancer (NSCLC) comprising:
- obtaining a test sample from a subject suffering from NSCLC following surgical resection;
- determining the expression level of at least one biomarker from Table 1, Table 2 and Table 3 in the test sample;
- and
- analyzing the expression level to generate a risk score, wherein the risk score can be used to provide a prognosis of the subject.
A method of predicting prognosis in a subject with non-small cell lung cancer (NSCLC) following surgical resection, comprising determining expression of one or more biomarkers listed in Table 1, Table 2 and/or Table 3, wherein an increase in expression of one or more biomarkers listed in Table 2 and/or Table 3 and a decrease in expression of one or more of the biomarkers listed in Table 1 compared to a control is used to predict whether the subject is in a high risk group having poor survival or a low risk group having good survival.
A method of selecting a therapy for a subject with NSCLC, comprising
- obtaining a test sample from a subject suffering from NSCLC who has undergone a resection;
- determining the expression level of at least two or more biomarkers identified in Table 2 in the test sample to generate an expression value for each gene;
- and
- analyzing the expression value to generate a risk score, wherein the risk score can be used to classify whether the subject is selected to receive an angiogenesis inhibitor.
A method of selectively treating a subject having NSCLC cancer, comprising:
- obtaining a test sample from a subject suffering from NSCLC following surgical resection;
- determining the expression level of at least one or more biomarkers identified in Table 1, Table 2 or Table 3, or any combination of biomarkers identified in Table 1, Table 2 or Table 3 in the test sample to generate a risk score;
- classifying the subject based on the risk score into a high risk group or a low risk group;
- and
- administering adjuvant therapy to the subject classified as belonging to the high risk group or administering no adjuvant therapy to the subject classified as belonging to the low risk group.
A kit for comprising a plurality of agents for measuring the expression of one or more biomarkers identified in Table 1, Table 2 and/or Table 3 and instructions for use
A kit for predicting whether a subject with lung cancer would benefit from adjuvant therapy, the kit comprising:
- a plurality of agents for measuring the expression of one or more biomarkers identified in Table 1, Table 2 and/or Table 3;
- means for analyzing the expression and generating a risk score to predict whether a patient would benefit from adjuvant therapy.
An array comprising one or more polynucleotide probes complementary and hybrdizable to an expression product of at least two biomarkers shown in Table 1, Table 2 and/or Table 3.
A composition comprising a plurality of isolated nucleic acid sequences, wherein each isolated nucleic acid sequence hybridizes to an RNA product of the biomarkers CBX7, STX1A, and TPX2, wherein the composition is used to measure the level of RNA expression of the three genes.
A computer product for predicting a prognosis a subject with NSCLC comprising:
- means for receiving data corresponding to the expression level of one or more biomarkers in a sample from a subject having NSCLC, wherein the one or more biomarkers are identified in Table 1, Table 2 and/or Table,
- means for generating an expression value for each gene;
- and
- means for generating a risk score based on inputting the expression value into a database comprising a reference expression profile associated with a prognosis, wherein the risk score predicts a prognosis of survival or classifies the subject into a high risk group or a low risk group.
Dependencies are inferred from the claim text.